Insider Buying: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Acquires 216,406 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bvf Partners L. P/Il purchased 216,406 shares of Kymera Therapeutics stock in a transaction dated Thursday, November 2nd. The shares were purchased at an average cost of $11.64 per share, for a total transaction of $2,518,965.84. Following the transaction, the director now owns 2,552,306 shares in the company, valued at approximately $29,708,841.84. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Kymera Therapeutics Trading Up 0.9 %

Kymera Therapeutics stock opened at $14.40 on Tuesday. The firm has a market capitalization of $797.93 million, a P/E ratio of -5.02 and a beta of 1.66. Kymera Therapeutics, Inc. has a twelve month low of $9.60 and a twelve month high of $39.85. The stock’s fifty day simple moving average is $15.39 and its 200-day simple moving average is $21.54.

Institutional Investors Weigh In On Kymera Therapeutics

Several large investors have recently bought and sold shares of KYMR. Bank of New York Mellon Corp boosted its stake in shares of Kymera Therapeutics by 29.3% in the 1st quarter. Bank of New York Mellon Corp now owns 686,194 shares of the company’s stock valued at $29,041,000 after buying an additional 155,476 shares during the period. MetLife Investment Management LLC increased its stake in shares of Kymera Therapeutics by 57.0% during the first quarter. MetLife Investment Management LLC now owns 19,228 shares of the company’s stock worth $814,000 after buying an additional 6,981 shares during the period. Rhumbline Advisers raised its holdings in Kymera Therapeutics by 7.4% in the first quarter. Rhumbline Advisers now owns 36,208 shares of the company’s stock valued at $1,532,000 after acquiring an additional 2,481 shares in the last quarter. BlackRock Inc. lifted its stake in Kymera Therapeutics by 0.6% in the first quarter. BlackRock Inc. now owns 3,419,084 shares of the company’s stock worth $144,698,000 after acquiring an additional 21,544 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in Kymera Therapeutics by 266.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 237,731 shares of the company’s stock worth $10,060,000 after acquiring an additional 172,839 shares in the last quarter.

Wall Street Analyst Weigh In

KYMR has been the subject of several recent analyst reports. Morgan Stanley cut their target price on Kymera Therapeutics from $39.00 to $37.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 29th. Piper Sandler cut their price objective on Kymera Therapeutics from $58.00 to $38.00 and set an “overweight” rating for the company in a research report on Friday. Stifel Nicolaus upped their target price on shares of Kymera Therapeutics from $48.00 to $52.00 and gave the company a “buy” rating in a research report on Monday, August 7th. Credit Suisse Group lifted their price target on shares of Kymera Therapeutics from $36.00 to $37.00 and gave the company a “neutral” rating in a research report on Friday, August 4th. Finally, HC Wainwright reduced their price target on shares of Kymera Therapeutics from $85.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $40.60.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.